Back to search results

ASCEND-CRC: Understanding and Treating Metastatic Colorectal Cancer

This study, called ASCEND-CRC, is for people with metastatic colorectal cancer (cancer that has spread). It aims to understand why some tumors become resistant to treatment and to test if certain drug combinations can better control the disease. Researchers will collect blood and tissue samples, and you may receive standard treatments like Bevacizumab, Cetuximab, Panitumumab, or FOLFIRI (chemotherapy). To join, you must have colorectal cancer that is not MSI-H/pMMR (a specific genetic marker) and is measurable and biopsy-able. The main goal is to see how safe these treatments are and what side effects occur over about one year. The study is currently unclear on its recruitment status and plans to enroll 100 participants.

Study design
This is an interventional study with a planned enrollment of 100 participants. The phase of the study is not specified.
What's involved
You would undergo blood draws, biopsies, and MRI scans. The safety and side effects will be measured through study completion, which is an average of one year.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events (side effects) will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07318389

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Not Yet Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~100 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:SOC (Standard of care)BevacizumabCetuximabPanitumumabFOLFIRIFOLFOX

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Dynamic Tumor Resistance
Metastatic Colorectal Cancer

Explore related trials

Colorectal CarcinomaMSI1 Gene

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Scott Kopetz, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Scott Kopetz, MD
[email protected]
713-792-2828
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Pregnancy.
Participants with concurrent or recent (less than 1 year before consent) malignancies that have the potential to interfere with the study safety and/or endpoint assessments will be excluded.
Participants for whom there is an intent to proceed to curative therapy (i.e., resection) will be excluded.
Participants who have undergone treatment with both oxaliplatin and irinotecan in the metastatic setting will be excluded. Treatment with oxaliplatin in the adjuvant setting with relapse within 6 months will be counted as treatment in the metastatic setting for the purpose of this criterium.
For participants who have undergone treatment for metastatic disease, participants who have not progressed (clinically or radiographically) on the most recent therapy will be excluded.
Concurrent participation in any other interventional trial.

What this trial measures

  • safety and adverse events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0